SMARCA4 and lung carcinoma: Moreover, the co-mutation of SMARCA4, TP53, STK11, and KRAS, which indicated a poor prognosis in lung cancer patients, occurred significantly more frequently in the high ICDrisk subtype (12.4%) than in the low ICDrisk subtype (4.2%) (p < 0.01, Figure 5e).